This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bagheri-Yarmand, R. Articles by Crépin, M. Search for Related Content PubMed PubMed Citation Articles by Bagheri-Yarmand, R. Articles by Crépin, M.

Carboxymethyl Benzylamide Dextran Blocks Angiogenesis of MDA-MB435 Breast Carcinoma Xenografted in Fat Pad and Its Lung Metastases in Nude Mice¹

Laboratoire d’Oncologie et Imagerie des Tumeurs Solides, Faculté de Médecine de Bobigny, Université Paris 13, 93017 Bobigny Cedex [R. B-Y., Y. K., A. M. R., R. V., M. C.]; Service d’Anatomie Pathologie, 93017 Bobigny Cedex [A. M.]; Laboratoire de Recherche sur les Macromolécules, Centre National de la Recherche Scientifique, URA 502, Université Paris-Nord, 93430 Villetaneuse [J. J.]; and Institut National de la Santé et de la Recherche Médicale U353, Institut d’Hématologie, Hôpital Saint-Louis, 75010 Paris [C. S., H. L.] France

We previously showed that carboxymethyl benzylamide dextran (CMDB7) prevents tumor growth and tumor angiogenesis by binding to angiogenic growth factors, thereby preventing them from reaching their receptors on tumor or stromal cells (Bagheri-Yarmand et al. Br. J. Cancer, 78: 111–118, 1998; Bagheri-Yarmand et al. Cell Growth Differ., 9: 497–504, 1998). In this study, CMDB7 inhibited neovessel formation within the fibroblast growth factor 2-enriched matrigel in mice, and its anticancer effect was then tested in a metastatic breast cancer model. Human MDA-MB435 cells were injected into the mammary fat pad of nude mice, and breast tumors developed within 1 week; all of the mice had lung metastases at 12 weeks. CMDB7 treatment (50, 150, or 300 s.c. or 300 i.v. mg/kg/week for 10 weeks) reduced the incidence of lung metastases to 12%. Histological analysis showed markedly less tumor neovascularization in the CMDB7-treated mice. Pulmonary metastasis incidence was strongly dependent on the intratumoral neoangiogenesis in primary tumors.

This article has been cited by other articles:

				J. L. Cook, T. A. Miura, D. N. Ikle, A. M. Lewis Jr., and J. M. Routes E1A Oncogene-induced Sensitization of Human Tumor Cells to Innate Immune Defenses and Chemotherapy-induced Apoptosis in Vitro and in Vivo Cancer Res., June 15, 2003; 63(12): 3435 - 3443. [Abstract] [Full Text] [PDF]

				Y. Hamma-Kourbali, R. Vassy, A. Starzec, V. Le Meuth-Metzinger, O. Oudar, R. Bagheri-Yarmand, G. Perret, and M. Crepin Vascular Endothelial Growth Factor 165 (VEGF165) Activities Are Inhibited by Carboxymethyl Benzylamide Dextran That Competes for Heparin Binding to VEGF165 and VEGF165{middle dot}KDR Complexes J. Biol. Chem., October 19, 2001; 276(43): 39748 - 39754. [Abstract] [Full Text] [PDF]

				R. Bagheri-Yarmand, Y. Hamma-Kourbali, P. Bissieres, J.-F. Morere, and M. Crepin Carboxymethyl Benzylamide Dextran and Tamoxifen Combination Inhibits Tumor Growth and Angiogenesis Clin. Cancer Res., June 1, 2001; 7(6): 1805 - 1811. [Abstract] [Full Text] [PDF]

				M. Yang, E. Baranov, X.-M. Li, J. W. Wang, P. Jiang, L. Li, A. R. Moossa, S. Penman, and R. M. Hoffman Whole-body and intravital optical imaging of angiogenesis in orthotopically implanted tumors PNAS, February 27, 2001; 98(5): 2616 - 2621. [Abstract] [Full Text] [PDF]

				R. Bagheri-Yarmand, R. K. Vadlamudi, R.-A. Wang, J. Mendelsohn, and R. Kumar Vascular Endothelial Growth Factor Up-regulation via p21-activated Kinase-1 Signaling Regulates Heregulin-beta 1-mediated Angiogenesis J. Biol. Chem., December 8, 2000; 275(50): 39451 - 39457. [Abstract] [Full Text] [PDF]